news
New drug makes aging clocks read younger in clinical trial
Rentosertib, a new drug for idiopathic pulmonary fibrosis, just made six different proteomic aging clocks tick backward in a clinical trial. Researchers published the findings in Nature Biotechnology, noting a clear biological age signal, separate from the primary treatment effect. This pushes the question of geroprotective effects into clinical testing.
Rentosertib, a new drug for idiopathic pulmonary fibrosis, just made six different proteomic aging clocks tick backward in a clinical trial. Researchers published the findings in Nature Biotechnology, noting a clear biological age signal, separate from the primary treatment effect. This pushes the question of geroprotective effects into clinical testing.
The architecture take
I keep seeing these 'aging clock' headlines, and my first thought is always, how much of that is just treating the disease, and how much is truly slowing down time? This new data from Rentosertib for IPF is interesting because multiple proteomic clocks showed a younger biological age signal. That's a good step toward validating these clocks in a human trial. The real trick is untangling whether the drug is making someone biologically younger, or if it's just making a very sick person less sick, which naturally makes their body markers look better. For me, the next thing to watch is how they design trials to isolate pure geroprotection from the primary therapeutic effect. Otherwise, every successful drug for a chronic illness could claim 'anti-aging,' and that feels like a stretch.